PT - JOURNAL ARTICLE AU - Heather M. Berens AU - Kristen J. Polinski AU - Ted R. Mikuls AU - Sonia Khatter AU - Justin August AU - Ashley Visser AU - Michael Mahler AU - Michael H. Weisman AU - James R. O’Dell AU - Richard M. Keating AU - Jane H. Buckner AU - Peter K. Gregersen AU - Jill M. Norris AU - V. Michael Holers AU - Kevin D. Deane AU - M. Kristen Demoruelle TI - Anticyclic Citrullinated Peptide Antibodies 3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis AID - 10.3899/jrheum.180897 DP - 2019 Dec 01 TA - The Journal of Rheumatology PG - 1556--1559 VI - 46 IP - 12 4099 - http://www.jrheum.org/content/46/12/1556.short 4100 - http://www.jrheum.org/content/46/12/1556.full SO - J Rheumatol2019 Dec 01; 46 AB - Objective. We investigated the association of age and anticyclic citrullinated peptide antibodies (anti-CCP) in subjects without rheumatoid arthritis (RA).Methods. Serum was tested for anti-CCP3.1 (IgG/IgA) in 678 first-degree relatives (FDR) of patients with RA and 330 patients with osteoarthritis (OA). Individual isotypes (anti–CCP-IgA and anti–CCP-IgG) were also tested in all FDR.Results. In FDR, increasing age was significantly associated with positivity for anti-CCP3.1 (per year, OR 1.03) and anti–CCP-IgA (per year, OR 1.05) but not anti–CCP-IgG. In FDR and OA subjects, anti-CCP3.1 prevalence was significantly increased after age 50 years.Conclusion. Increasing age in individuals without RA should be considered in the interpretation of anti-CCP3.1 positivity.